MRI/US fusion transperineal versus transrectral biopsy of prostate cancer: Outcomes and complication rates, a tertiary medical center experience in the Middle East
Open Access
- 1 March 2022
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 48 (2) , 98-105
Abstract
Objective: To report on the outcomes of transperineal versus transrectal magnetic resonance imaging/ultrasound fusion biopsy of the prostate including detection of clinically significant cancer and complications. This is the first and largest series in the Middle East. Material and methods: Between May 2019 and June 2020, 145 patients with suspicious lesions on magnetic resonance imaging underwent magnetic resonance imaging/ultrasound fusion prostate biopsy at our center. Transperineal biopsy was performed under light sedation, while transrectal biopsy patients had a periprostatic block for anesthesia. Clinically significant cancer was defined as Gleason ≥3+4 Results: In all, 98 transperineal biopsies and 47 transrectal magnetic resonance imaging/ultrasound fusion prostate biopsies were done. Patients had similar prebiopsy parameters (transperineal vs. transrectal): median age (64.5 vs. 66 years; P=.68), median prostate-specific antigen value (7.5 vs. 7.5; P=.42), and median prostate volume (51 vs. 52.5; P=.83). Those that underwent transperineal biopsy had fewer average total number of cores compared to transrectal ultrasound-guided biopsy (11 vs. 13; P=.025) fewer average number of random cores (3 vs. 6; P < .0001), and the detection rate of clinically significant cancer was similar between the groups (44% vs. 48.9%; P=.57). No difference in hematuria, retention, and sepsis rate requiring admission (1 vs. 2; P=.2) was observed. However, more patients had urinary tract infection in the transrectal ultrasound-guided biopsy group compared to transperineal biopsy group (5 vs. 1; P=.006) that were treated with antibiotics on outside basis. Conclusion: Magnetic resonance imaging/ultrasound transperineal fusion biopsy has similar detection rate of clinically significant cancer compared to transrectal ultrasound-guided biopsy with less urinary tract infection post biopsy. Cite this article as: El-Achkar A, Abou Heidar N, Labban M, et al. MRI/US fusion transperineal versus transrectral biopsy of prostate cancer: Outcomes and complication rates, a tertiary medical center experience in the middle east. Turk J Urol. 2022;48(2):98-105.Keywords
This publication has 40 references indexed in Scilit:
- In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12‐core biopsy still necessary in addition to a targeted biopsy?BJU International, 2015
- Hospital admissions after transrectal ultrasound‐guided biopsy of the prostate in men diagnosed with prostate cancer: A database analysis in EnglandInternational Journal of Urology, 2014
- Value of Targeted Prostate Biopsy Using Magnetic Resonance–Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific AntigenEuropean Urology, 2014
- Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy?BJU International, 2013
- Morbidity After Transperineal Prostate Biopsy in 3000 Patients Undergoing 12 vs 18 vs More Than 24 Needle CoresUrology, 2013
- Multiparametric MRI and prostate cancer diagnosis and risk stratificationCurrent Opinion in Urology, 2012
- Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy-should we reassess our practices for antibiotic prophylaxis?Clinical Microbiology and Infection, 2012
- High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound‐guided template saturation biopsyBJU International, 2012
- Complications After Prostate Biopsy: Data From SEER-MedicareJournal of Urology, 2011
- Incidence of Urinary Tract Infection Following Transrectal Ultrasound Guided Prostate Biopsy at a Tertiary-Care Medical Center in LebanonInfection Control, 2004